title: Pharmacogenetics of the G protein-coupled receptors.
abstract: Pharmacogenetics investigates the influence of genetic variants on physiological phenotypes related to drug response and disease, while pharmacogenomics takes a genome-wide approach to advancing this knowledge. Both play an important role in identifying responders and nonresponders to medication, avoiding adverse drug reactions, and optimizing drug dose for the individual. G protein-coupled receptors (GPCRs) are the primary target of therapeutic drugs and have been the focus of these studies. With the advance of genomic technologies, there has been a substantial increase in the inventory of naturally occurring rare and common GPCR variants. These variants include single-nucleotide polymorphisms and insertion or deletions that have potential to alter GPCR expression of function. In vivo and in vitro studies have determined functional roles for many GPCR variants, but genetic association studies that define the physiological impact of the majority of these common variants are still limited. Despite the breadth of pharmacogenetic data available, GPCR variants have not been included in drug labeling and are only occasionally considered in optimizing clinical use of GPCR-targeted agents. In this chapter, pharmacogenetic and genomic studies on GPCR variants are reviewed with respect to a subset of GPCR systems, including the adrenergic, calcium sensing, cysteinyl leukotriene, cannabinoid CB1 and CB2 receptors, and the de-orphanized receptors such as GPR55. The nature of the disruption to receptor function is discussed with respect to regulation of gene expression, expression on the cell surface (affected by receptor trafficking, dimerization, desensitization/downregulation), or perturbation of receptor function (altered ligand binding, G protein coupling, constitutive activity). The large body of experimental data generated on structure and function relationships and receptor-ligand interactions are being harnessed for the in silico functional prediction of naturally occurring GPCR variants. We provide information on online resources dedicated to GPCRs and present applications of publically available computational tools for pharmacogenetic studies of GPCRs. As the breadth of GPCR pharmacogenomic data becomes clearer, the opportunity for routine assessment of GPCR variants to predict disease risk, drug response, and potential adverse drug effects will become possible.
authors.affiliation: Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, Canada, M5S 1A8, miles.thompson@utoronto.ca.
authors.forename: Miles D
authors.initials: MD
authors.lastname: Thompson
authors.forename: David E C
authors.initials: DE
authors.lastname: Cole
authors.forename: Valerie
authors.initials: V
authors.lastname: Capra
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Siminovitch
authors.forename: G Enrico
authors.initials: GE
authors.lastname: Rovati
authors.forename: W McIntyre
authors.initials: WM
authors.lastname: Burnham
authors.forename: Brinda K
authors.initials: BK
authors.lastname: Rana
mesh_terms: D030541:Databases, Genetic; D056726:Genetic Association Studies; D006801:Humans; D009154:Mutation; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D043562:Receptors, G-Protein-Coupled / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism
chemical_list: D043562:Receptors, G-Protein-Coupled